SINOVAC 管理层关于审计师辞职的声明

SINOVAC 管理层关于审计师辞职的声明

(SeaPRwire) - 北京,2025年4月22日 -- 致科兴生物制药有限公司的股东及其他利益相关者: 科兴生物制药有限公司 (NASDAQ: SVA, “SINOVAC” 或 “公司”) 管理层近期收到其外部审计师的通知,决定辞去公司2024财年终审计的职务。 根据辞职信,审计师的决定是由公司现任董事会于2025年4月1日发布的一项声明引发的,该声明称“现任董事会正在评估公司前任董事在卸任后采取的某些公司行为”。审计师表示担心,此类审查会引入不确定性,影响其审计意见所依据的事实和法律基础。由于审计师辞职,公司将无法在2025年4月30日截止日期前向美国证券交易委员会 (“SEC”) 提交Form 20-F年度报告。 这一事态发展令人深感担忧,因为它反映出现任董事会的行为已经扰乱了公司合规运营和治理。董事会启动此项审查的理由似乎是基于英国枢密院于2025年1月16日作出的一项裁决。该裁决除其他事项外,认定一群股东在公司2018年年度股东大会上提名的董事候选人名单是有效任命的。然而,目前的董事会组成并未反映该名单。在最近披露的五名董事中,只有三名是该名单的一部分,其中一名目前因犯有挪用公款、伪造政府文件和印章以及伪造公司印章罪而被拘留。多位股东对现任董事会的资格、合法性及其作为公司董事会的权力提出了严重质疑。 虽然我们尊重英国枢密院的裁决,但作为公司管理层,我们认为维护公司的稳定和有序运营符合所有股东和利益相关者的最大利益。虽然枢密院的裁决确认了某些股东在公司2018年年度股东大会上提名的董事候选人名单的有效性,但它并未推翻前任董事会自2018年2月以来采取的任何公司行为。 事实上,正是在前任董事会的领导下,SINOVAC 实现了巨大的增长,扩展到多个国际市场,并显着提高了收入和股东价值。管理团队支持向股东分配现金股息,如果没有前任董事会的倡议和成就,这是不可能实现的。任何试图推翻或逆转前任董事会采取的公司行动,不仅会造成运营混乱和法律不确定性,还会损害公司未来的增长。审计师的辞职以及由此导致的Form 20-F文件提交延迟,是不稳定可能造成的损害的不幸例证。 在这个关键时刻,鉴于对某些现任董事会成员的资格及其任命程序的潜在担忧,以及他们近期行为对公司持续运营和长期稳定造成的破坏性影响,我们呼吁所有股东进行合作、协调和前瞻性的视角。我们认为,应尽快召开股东大会,选举产生一个新的董事会,为SINOVAC提供强大、稳定和合法的领导,以推动公司向前发展。同时,我们也呼吁并支持尽快恢复公司股票的正常交易。 作为一家上市公司的管理团队,我们有信义义务以所有股东的最佳利益行事。鉴于最近的事态发展,我们认为有责任发布此公开声明,以确保透明度,并使股东和利益相关者充分了解这些重要事项。 我们仍然致力于服务SINOVAC及其所有股东的长期利益。为了公司的合规运营和治理,我们将积极协助聘请一家新的独立注册会计师事务所。 – SINOVAC管理层 2025年4月22日,北京本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。 联系方式:SINOVAC管理层 Sinovac Holding Group Co., Ltd. +86(010)82799800 sinovac@sinovac.com ```
More
更新 — AP Biosciences将在美国癌症研究协会年会上展示新的临床前数据

“`

更新 — AP Biosciences将在美国癌症研究协会年会上展示新的临床前数据 “`

(SeaPRwire) - 台北,台湾,2025年4月21日 -- AP Biosciences,一家致力于通过创新双特异性抗体改变癌症治疗的临床阶段生物制药公司,今天宣布,它将在即将于2025年4月25日至30日在伊利诺伊州芝加哥举行的美国癌症研究协会 (AACR) 年会上,以海报形式展示临床前摘要。 数据将展示AP402的潜力,这是一种同类首创的下一代T细胞接合器,靶向体内和体外研究中的CD137和p95HER2。 AP402于今年二月获得了在澳大利亚开始临床试验的IND许可。 海报展示的详细信息如下: 标题:AP402,一种靶向p95HER2和CD137的双特异性抗体,显示出强大的抗肿瘤活性海报编号:6016演讲者:黄柏霖博士,抗体发现副主任会议:临床研究,治疗性抗体,包括工程抗体2地点:海报区35日期和时间:2025年4月29日下午2:00 – 5:00 会后,海报将在AP Biosciences网站上提供。 关于AP402 AP402是由AP Biosciences发起并开发的一种同类首创的双特异性抗体,靶向p95HER2,一种HER2的截短变体,在30-40%的耐药HER2阳性癌症中表达。 AP402将p95HER2结合与CD137激活域相结合,以实现仅在肿瘤微环境内的靶标依赖性T细胞激活。这种设计有助于HER2变体的聚集,从而有效触发CD137介导的T细胞激活,同时最大限度地减少与全身性细胞因子释放相关的潜在毒性。 p95HER2和CD137的结合域旨在增强表达HER2变体的癌细胞和表达CD137的T细胞之间的桥接,确保有效的免疫细胞募集,而不会产生空间阻碍。这种新颖的机制使AP402成为一种有希望的治疗方法,可以解决对传统抗HER2疗法产生耐药性的肿瘤,为难治性/复发性癌症患者提供潜在的新希望。 关于AP Biosciences AP Biosciences是一家位于台湾的临床阶段生物制药公司,致力于开发用于癌症和其他疾病的创新抗体疗法。 AP Biosciences应用其专有的Omni-Mab和T-cube平台,正在率先开发下一代双特异性抗体,以在需要的地方精确激活免疫系统,从而治疗已确诊和耐药性癌症。 AP Biosciences联系方式Spike LoAP Biosciences+886-2-2653-2886 媒体联系方式Jason Braco, PhDLifeSci Communications(908)-432-4243本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Meiwu Technology Company Limited 重新符合纳斯达克最低收盘价规则

“`

Meiwu Technology Company Limited 重新符合纳斯达克最低收盘价规则 “`

(SeaPRwire) - 深圳,中国,2025年4月21日 -- Meiwu Technology Company Limited (“WNW”或“公司”), (NASDAQ: WNW) 今日宣布,其已收到来自纳斯达克股票市场有限责任公司(“Nasdaq”)的正式通知,公司已重新符合纳斯达克上市规则5550(a)(2)的规定,该规则要求公司的每股普通股(无面值)(“普通股”)维持最低1.00美元的买入价。 纳斯达克工作人员在确定公司普通股的收盘买入价已在2025年4月1日至2025年4月14日期间连续10个工作日达到或高于每股1.00美元后,做出了此合规性决定。 因此,公司已重新符合纳斯达克上市规则5550(a)(2)的规定,并且此投标价格缺陷问题现已结束。 关于Meiwu Technology Company Limited Meiwu Technology Company Limited 是一家于2018年12月4日在英属维尔京群岛注册成立的公司。 美物已实施战略转型,将其业务从精选优质食品的在线销售和短信服务转变为护肤行业,目前通过厦门春尚健康科技有限公司(“Chunshang Xiamen”)销售功能性护肤产品,Chunshang Xiamen 是美物在中国的间接全资子公司。 安全港声明 本新闻稿中的某些陈述构成经修订的1995年《美国私人证券诉讼改革法案》中“安全港”条款含义内的“前瞻性陈述”。在本新闻稿中,诸如“估计”、“预计”、“期望”、“预期”、“预测”、“计划”、“打算”、“相信”、“寻求”、“可能”、“将”、“应该”、“未来”、“提议”等词语及其变体或类似表达(或此类词语或表达的否定形式)旨在识别前瞻性陈述。这些前瞻性陈述并非对未来业绩、状况或结果的保证,并且涉及许多已知和未知的风险、不确定性、假设和其他重要因素,其中许多因素是公司无法控制的,可能导致实际结果或结果与前瞻性陈述中讨论的结果或结果存在重大差异。重要因素除其他外包括:管理增长的能力;识别和整合其他未来收购的能力;未来获得额外融资以资助资本支出的能力;一般经济和商业状况的波动;不利影响我们盈利能力的成本或其他因素;涉及专利、知识产权和其他事项的诉讼;立法和监管环境的潜在变化;大流行或流行病。本新闻稿中包含的前瞻性陈述还受到其他风险和不确定性的影响,包括公司向美国证券交易委员会提交的文件中更全面描述的那些风险和不确定性,这些文件可在查阅。除非适用法律要求,否则公司不承担更新或修改任何前瞻性陈述的义务,无论是由于新信息、未来事件或其他原因。此类信息仅代表本新闻稿发布之日的情况。 联系方式Meiwu Technology Company LimitedZhichao YangEmail: 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Everbright Digital Holding Limited 宣布首次公开募股完成

“`

Everbright Digital Holding Limited 宣布首次公开募股完成 “`

` tags. (SeaPRwire) - 香港,2025年4月21日 -- 总部位于香港的综合营销解决方案提供商Everbright Digital Holding Limited(“公司”或“Everbright”)今天宣布,已完成首次公开发行(“本次发行”),以每股4.00美元的公开发行价格发行1,500,000股普通股,每股面值0.00004美元(“普通股”)。普通股于2025年4月17日在纳斯达克资本市场开始交易,股票代码为“EDHL”。 公司从本次发行中出售的普通股获得总收益600万美元,未扣除承销折扣和其他相关费用。此外,公司已授予承销商一项为期45天的期权,允许其按公开发行价格(扣除承销折扣)购买最多额外225,000股普通股。 公司将把本次发行所得的净收益用于营销和业务扩张、持续研发我们的核心技术、海外业务拓展、人才引进和培训,以及一般运营资金和公司用途。 本次发行以包销方式进行。Dominari Securities LLC 担任本次发行的主承销商,Revere Securities LLC 担任联席承销商。Pacific Century Securities, LLC 担任公司顾问。Ortoli Rosenstadt LLP 担任公司美国律师,Hunter Taubman Fischer & Li LLC 担任承销商的美国证券律师。 与本次发行相关的F-1表格注册声明已提交给美国证券交易委员会(“SEC”)(文件编号:333-285191),经修订后,于2025年3月31日被SEC宣布生效。本次发行仅通过招股说明书进行,招股说明书构成注册声明的一部分。有关本次发行的最终招股说明书副本可发送电子邮件至info@dominarisecurities.com从 Dominari Securities LLC 获取,或通过标准邮件发送至 Dominari Securities LLC, 725 Fifth Avenue, 23rd Floor, New York, NY 10022,或致电 (212) 393-4500。此外,也可以通过SEC网站获取与本次发行相关的最终招股说明书。 在您投资之前,您应该阅读公司已向或将向SEC提交的招股说明书和其他文件,以获取有关公司和本次发行的更多信息。本新闻稿不构成出售要约或购买公司任何证券的要约邀请,也不得在任何州或司法管辖区内出售公司的任何证券,如果在该州或司法管辖区根据证券法进行注册或获得资格之前,此类要约、邀请或出售将是非法的。 关于Everbright Digital Holding Limited Everbright Digital Holding Limited 是一家总部位于香港的综合营销解决方案提供商。公司通过其运营子公司Hong Kong United Metaverse Limited在香港开展所有业务。该公司是香港一家深度参与元宇宙及相关技术的综合营销解决方案提供商,提供一站式数字营销服务,以支持企业发展的每个阶段,包括元宇宙模拟、虚拟现实(VR)和增强现实(AR)设计和创作、创意活动策划和管理、IP角色创建和社交媒体营销。 欲了解更多信息,请访问公司网站:. 前瞻性陈述 本公告中的某些陈述为前瞻性陈述。这些前瞻性陈述涉及已知和未知的风险和不确定性,并且基于公司目前对可能影响其财务状况、经营业绩、业务战略和财务需求的未来事件的预期和预测。投资者可以通过使用诸如“近似”、“相信”、“希望”、“期望”、“预期”、“估计”、“预计”、“打算”、“计划”、“将”、“会”、“应该”、“可能”或其他类似表达方式在本招股说明书中找到许多(但并非全部)此类陈述。除非法律要求,否则公司不承担公开更新或修订任何前瞻性陈述以反映后续发生的事件或情况或其预期变化的义务。尽管公司认为这些前瞻性陈述中表达的预期是合理的,但不能向您保证这些预期将被证明是正确的,并且公司提醒投资者,实际结果可能与预期结果存在重大差异,并鼓励投资者审查可能影响公司未来业绩的其他因素,这些因素包含在公司向SEC提交的注册声明和其他文件中。 投资者和媒体垂询,请联系: Everbright Digital Holding LimitedLeung Chun Yip, CEO电子邮件:michael@umeta.hk本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Yocan 推出 ARI 2.0 系列:精准、掌控、多功能

Yocan 推出 ARI 2.0 系列:精准、掌控、多功能

(SeaPRwire) - 中国深圳,2025年4月21日 -- 今天发布了—新一代电源(ARI 2.0 Plus, ARI 2.0, ARI 2.0 Mini)—旨在提升电子烟体验的方方面面。在最初的ARI成功的基础上,新系列通过无与伦比的精确电压控制、实时OLED监控和先进的安全保护,为用户提供更强大的性能、个性化和安心的体验。 精确电压控制 每个ARI 2.0设备提供1.8 V–4.2 V可调电压,以0.1 V为增量,让用户可以微调他们的体验,从细腻的风味曲线到浓密的烟雾。侧面安装的“+”和“-”按钮使调整变得轻松,确保每次抽吸都恰到好处。 直观的OLED反馈 ARI 2.0清晰的OLED显示屏将基本信息(电池状态、精确电压和抽吸次数)直接放在用户的手指尖,消除了不确定性,并实现了更好的会话管理。实时可见性意味着用户可以主动调整设置,避免意外断电,并自信地监控消费模式。自动抽吸跟踪,在9,999次抽吸时无缝重置,支持长期使用意识,而无需手动监督。 智能预热和保护 ARI 2.0的智能预热功能以1.8 V的电压应用受控的10秒预热,确保较稠的油在第一次抽吸前达到最佳稠度——减少堵塞,并从一开始就提供更平滑、更可靠的吸食体验。集成的安全措施,包括防止过热的15秒切断以及不活动一小时后自动关闭,让用户可以更放心地享受他们的会话,同时最大限度地减少设备磨损并随着时间的推移节省电池寿命。 通用510兼容性 配备标准510螺纹,ARI 2.0系列适用于任何高于0.8 Ω的雾化器,为浓缩物爱好者提供可靠的连接和广泛的通用性。 可用型号和颜色 ARI 2.0 Plus (φ17 × 97 mm; 900 mAh)ARI 2.0 (φ14 × 94 mm; 650 mAh)ARI 2.0 Mini (φ14 × 80 mm; 400 mAh) 每个型号均提供黑色、白色、青色、紫色和粉色,以适应各种风格。找到您完美的ARI 2.0,按照您的意愿体验电子烟。 有关更多系列,请访问。 关于Yocan 自2013年以来,Yocan凭借创新设计、严格的质量标准和以用户为中心的解决方案引领着电子烟行业。Yocan致力于改进电子烟体验,不断开发先进的设备,以提高全球用户的性能、安全性和风格。 网站: Facebook: Instagram: YouTube: 联系方式: 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。 CONTACT: Jimmy Wen Yocan Technolog Co., Ltd info at yocantech.com
More
A Decade of Olympus India’s Commitment to Community Welfare

A Decade of Olympus India’s Commitment to Community Welfare

DELHI, Apr 22, 2025 - (JCN Newswire via SeaPRwire.com) - Olympus Medical Systems India Pvt. Ltd. (OMSI), an Olympus Group company, today announces the successful inauguration of newly constructed washrooms at eight government schools across major locations in India. This milestone is part of OMSI’s corporate social responsibility (CSR) initiative, the Water, Sanitation, and Hygiene (WASH) Program. By actively supporting community well-being and education through long-standing projects, OMSI and Olympus Corporation (Olympus), remain dedicated to supporting the next-generation education in India.Inauguration Ceremony at Government Middle School, Aklimpur, in Sohna Block of Gurugram District of Haryana, IndiaThe WASH Program, a decade-long CSR project by OMSI, focuses on enhancing school infrastructure by constructing and renovating washrooms to ensure that students—especially girls—have access to clean and safe sanitation facilities. This initiative addresses critical challenges in sanitation, hygiene, and child health that directly impact education. Several reports highlight that one in four girls in India drop out of school due to inadequate toilet facilities, underscoring the vital importance of this initiative for promoting gender equality and educational continuity. Over its fiscal year which ended in March 2025, the 10th year since the program began, OMSI constructed washrooms in eight government schools across four major locations—Delhi NCR, Kolkata, Chennai, and Mumbai. —This initiative provides improved sanitation facilities for over 2,700 students and ensures better hygiene standards for the school communities. The inauguration for these schools took place in March 2025, attended by OMSI leaders, school headmasters, and other officials. Over the past decade, the company has contributed to creating hygienic learning environments for approximately 7,000 students across 30 schools through this program.Nutrition kits handed over by Naoshi Kikumoto,MD, OMSIAdditionally, OMSI’s Olympus Arogya Bachpan (Disease-Free Childhood) Program, provided health check-ups, distributed nutrition kits, and held awareness sessions on essential topics such as personal hygiene and safety for approximately 450 students across two schools. This program, initiated in 2018, aims to improve student well-being through hygiene education, child safety awareness, and health check-ups, helping to combat malnutrition and instill lifelong healthy habits. Since its establishment in 2009, OMSI has remained committed to enhancing health, hygiene, and awareness through these activities, positively impacting thousands of children across India and enabling them to pursue their education in a safe and hygienic environment. “We at Olympus believe that every child deserves the opportunity to grow up healthy and to receive a quality education. Through our CSR programs, we are proud to contribute to a brighter, healthier future for children and communities across India," said Naoshi Kikumoto, Managing Director, OMSI. Together with Olympus, OMSI will continue advancing global corporate citizenship to make people's lives healthier, safer, and more fulfilling across India and beyond. Olympus’ Other CSR activities in India:Beyond its ongoing efforts in areas of hygiene and sanitation, OMSI also played a crucial role in supporting India’s healthcare infrastructure. In its fiscal year which ended in March 2025, the company supported the Saairaam Cancer Foundation in Salem, Tamil Nadu, and JIPMER (Jawaharlal Institute of Postgraduate Medical Education and Research), Pondicherry, by donating a Laparoscopic System and contributing to ENT (ear, nose and throat) cancer screening initiatives, respectively. These efforts aim to enhance cancer awareness, early detection, and treatment in underserved regions. During the COVID-19 pandemic, in its fiscal year ended in March 2021 and 2022, OMSI supported Civil Hospital Gurgaon, with Antigen Test Kits, Viral Transport Medium Kits, canopy tents for testing camps, and rental vehicles for transporting samples and lab technicians. The company also donated a fully equipped ambulance, solar lights and other essentials to support the Earth Saviours Foundation. Furthermore, OMSI focused on strengthening infrastructure at Primary Healthcare Centers (PHCs) in remote areas across the country. It also provided basic sanitation facilities at government hospitals in severely affected regions lacking such services. About Olympus At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global X account: @Olympus_Corp. Also visit LinkedIn page of OMSI.For media inquiries, please contact:Sanjana GroverOlympus Medical Systems India Pvt Ltdsanjana.grover@olympus.comhttps://www.olympus.in/ Public Relations GroupOlympus CorporationGlobal-Public_Relations@olympus.comhttps://www.olympus-global.com/Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com Copyright 2025 JCN Newswire via SeaPRwire.com.
More

北京能源国际2024年业绩:战略韧性筑基 创新效能引领绿色增长新范式

香港, 2025年4月22日 - (亚太商讯 via SeaPRwire.com) - 北京能源国际(00686.HK)(下称"京能国际")近期发布了2024全年业绩。笔者除了仔细阅览业绩公告外,还有幸作为嘉宾参与了业绩发布会并与公司高管们直接交流,不禁感叹:这一年,京能国际以"战略韧性坚守"与"效能革新驱动"双擎牵引,实现了多项经营数据里程碑式增长,交出了一份高质量发展的亮眼答卷。下面我将对京能国际2024业绩进行浅解读,抛砖引玉以供各位参考。一、业绩突破与战略深化:双轮驱动铸就增长里程碑京能国际主要从事发电站及其他清洁能源项目的开发、投资、运营及管理。其2024年全年总营收70.11亿元人民币,同比增长25.9%;年度溢利5.57亿元人民币,同比增长18.01%;发电装机容量 13,501兆瓦,同比增长47.5%;总发电量194.20亿千瓦时,同比增长40.9%;资本负债比率73.5%,同比下降320BP。2024年H2营收37.39亿元人民币,环比增长14.27%,同比增长24.88%;溢利2.65亿元人民币,同比增长17.78%;发电装机容量新增2,594兆瓦,环比增长76.70%,同比增长46.79%;发电量10,084,328兆瓦时,环比增长32.86%,同比增长45.82%。从上述数据可以看出,京能国际不仅2024年全年营收、溢利实现双双增长,而且2024年下半年财务表现亦可圈可点,同比增收又增利。特别值得注意的是,作为一家能源企业,京能国际在2024 H2的新增发电装机容量扩容迅猛,环比、同比增幅分别达到了惊人的76.70%、46.79%,反映了京能国际的项目开工及并网工作进展顺利。更进一步地,作为一家实体资产运营企业,项目开工顺利的背后,是强劲的现金流提供保证。但与此同时,京能国际的资本负债比率反而下降了3.2个百分点,这反映公司的盈利能力十分可观。基于从业绩公告中及业绩发布会上获得的公开信息,笔者认为:面对行业竞争加剧、经济形势复杂的大环境,过去一年京能国际成功实现总营收、净利润、装机容量、发电量、资产负债率"四增一降",成功实现夯实"国际化清洁能源生态投资运营商"这一发展定位的同时在降本增效、科技与数字化等多个方面取得可喜成就和良性发展,主要得益于管理层提出并坚定执行"聚焦主业、多元驱动、精益管理、创新创效"的战略。二、战略深耕:双环线筑基,全球化布局激活增长引擎"聚焦主业、多元驱动、精益管理、创新创效"不是一句空喊口号,在实际运营中,京能国际管理层又将其拆解为"双环线、一中心、一聚焦"的落地战略,来加速推进能源基地建设。2024年,京能国际双环线基地取得突破,规模化与协同效应凸显。北环线"吉电进京"项目(东北松辽清洁能源基地)配套火电预可研通过专家评审;内蒙古"蒙电进京"基地获得京蒙联合纳规研究,为跨区域绿电输送铺平道路。南环线聚焦长三角高收益市场,扬州1.56吉瓦光伏项目预收购协议落地,南通如东45万千瓦海上风电投资协议签署。南北双环线协同发力,形成"绿电进京"与"东部消纳"的双向赋能格局,规模化效应显著提升产业链协同效率。此外,京能国际还持续推动多业态协同发展,形成差异化竞争优势,进一步扩大市场影响力。公司突破单一风光业务,构建了"风电光伏+水电+燃机+综合能源(储能业务及电力交易代理业务)+绿氢"多元业态。水电领域,保山能源近1GW的水电项目自重组后收益良好,贡献了新的利润增长点;燃机业务以阳西项目为标杆,主机安装就位,计划投产后将实现"投产即盈利",此外还获得江门珠西分布式能源站项目的开发权;综合能源业务方面,共享储能业务初成规模,广西田阳、山东荣成与浙江萧山三个共享储能项目成功投运,公司自主设计开发的储能电池模块完成新国标产品认证;绿氢领域,宣钢制氢配套60兆瓦光伏项目开工建设。京能国际的海外布局也成果斐然,展示了强大的国际化资源整合能力。澳洲沃拉28万千瓦光伏项目全容量并网;完成澳洲资产40%股权交易,成为当地最大中资清洁能源企业。在深耕澳洲市场的同时,京能国际也正在积极推进欧洲新能源市场。实际上,笔者在发布会中直接与公司高管交流后,有这样一种感触:京能国际的能源"出海", 不仅为公司带来了利润贡献,而且顺应了中国企业通过走出国门参与全球技术与管理竞争而提升发展质量的历史趋势,具有非常强的战略前瞻性,值得国内企业学习借鉴。三、效能革新:精益运营与科技创新驱动全价值链升级笔者在前文提到,京能国际的盈利能力十分可观、现金流强劲。这主要得益于公司的"开源节流":除了能源主业造血能力十足、持续产生现金流和利润之外,公司在精细化运营以降本增效、抓住利率下行历史机遇以大力拓展融资等方面,也积极作为。通过精细化运营,京能国际成本管控效果明显。2024年,公司通过严控初设概算、推行集采模式,严控组件价格、加强EPC项目过程监督等方式共节约成本超5000万元。京能国际还在科技与数字化等软实力上精准投入来提升运营效率,从而实现压降成本。譬如,公司搭建及持续迭代经营计划管理系统、营销售电一体化平台、电力现货辅助决策系统、BI系统,既能实现生产、投资、经营数据的快速汇总、数据交互、追根溯源及可视化,为公司经营管理决策提供精准支撑、降低运维成本,又能提升现货交易水平,并在提升电力结算价格上取得明显成效。京能国际的资本运作也十分顺利,财务费用获得有力压降,资本结构和负债结构获得显著优化。京能国际2024年维持了良好信用,保持了境内联合资信"AAA"级、境外标普"BBB+"级和惠誉"A"级评级;成功发行50亿元熊猫永续债;旗下子公司发行10亿元中期票据,仅为2.35%的利率创北京市属企业及电力行业同评级同期限最低;保山水电REITs扩募获得推进,资产证券化率持续提升。。公司年度在境内外新增融资213.39亿元,平均利率2.69%;在境外新增融资83.18亿元;存量高息融资优化158.74亿元。结语经过笔者上文抛砖引玉,不难看出,2024年,北京能源国际(00686.HK)以"战略韧性"筑基、"效能革新"破局,在全球能源变局中实现规模与质量的双重跃升。而根据年报展望,2025年,北京能源国际将以"提质增效年"为牵引,深化双环线基地产能释放,加速吉电、蒙电项目落地;推动绿氢与储能商业化进程,拓展高收益区域共享储能;依托澳洲、欧洲8等项目规模化,持续扩大国际影响力。在"双碳"目标时限趋近、能源革命日行千里、利率渐次下行的历史机遇背景下,笔者对北京能源国际2025年的运营与发展充满信心,认为其在资本市场的表现亦值得多一分期待与耐心。 Copyright 2025 亚太商讯 via SeaPRwire.com.
More

云顶新耀”摘B”成功 盈利能力与创新价值获双重验证

香港, 2025年4月22日 - (亚太商讯 via SeaPRwire.com) - 今日,云顶新耀(HKEX 1952.HK)宣布公司已获香港联交所批准,将"B"标记从股票代码中移除。此举不仅标志着公司在市值与收入等方面达到了更高标准,更向资本市场释放出强劲的盈利能力与持续增长潜力的明确信号。自香港联交所2018年推出18A上市机制以来,已有逾60家生物科技企业在港交所上市,但成功移除"B"标记的企业数量仍然有限。根据香港联交所规定,18A公司需满足年收入不低于5亿港元、市值不低于40亿港元的标准,方可申请摘除"B"标记。这一要求不仅是对企业财务表现的衡量,同时也反映了其盈利能力、产品研发进展及商业化成熟度。2024年,云顶新耀持续深化"双轮驱动"战略,已由精准引进海外产品进入到具有出海潜力的自主研发和授权引进的并进模式,专注高价值"蓝海"领域的同时,致力于研发同类首创或同类最佳的创新疗法。根据最新年报业绩,公司全年总收入同比大幅增长461%至人民币7.067亿元,超额完成7亿元的既定目标,并首次实现年度商业化层面盈利。三款已上市产品表现亮眼:耐赋康(R)实现销售额3.534亿元,同比增长1581%;依嘉(R)收入达3.528亿元,同比增长256%;伊曲莫德(VELSIPITY(R))已在中国澳门和新加坡获批上市,并通过"港澳药械通"政策成功进入粤港澳大湾区,其新药上市申请亦于2024年12月分别在中国大陆(商品名:维适平™)与中国香港(商品名:维长宁™)获得正式受理。在持续夯实商业化基础的同时,云顶新耀积极推进自研及全球权益产品差异化管线布局。公司自主研发的新一代共价可逆BTK抑制剂EVER001展现出积极的临床数据,全球开发进程稳步推进。在AI+mRNA平台方面,公司在肿瘤及自身免疫治疗领域实现了从基础研究到全球临床转化的里程碑突破,充分验证了其自主研发实力、AI+mRNA技术平台的创新优势以及全球价值。其中,自研的个性化肿瘤治疗性疫苗EVM16已进入临床阶段,并于今年3月完成首例患者给药;通用型现货肿瘤治疗性疫苗EVM14的新药临床试验申请已获美国FDA批准,成为公司首款自研进入全球临床阶段的mRNA肿瘤治疗性疫苗;自体生成CAR-T项目也将于今年完成首个临床前候选药物筛选。中金公司在最新研报中指出,云顶新耀的业务重心精准聚焦于肾病治疗和mRNA肿瘤疫苗领域,预计其核心产品组合的增长将持续超越市场预期。鉴于公司盈利能力的提升和产品估值的体现,中金上调其目标价至70港元,并维持"跑赢行业"评级。云顶新耀此次"摘B",不仅标志着其财务表现与商业化能力获得资本市场认可,更有望吸引更多机构投资者关注,进一步提升公司在二级市场的流动性与配置价值。凭借稳健增长的营收表现、持续增强的盈利能力,以及基于卓越运营体系构建的商业化平台所带来的强劲"造血"能力,云顶新耀正持续巩固其在核心治疗领域的领先地位,并加速推进AI+mRNA技术平台的创新转化。随着更多高潜力产品进入收获期,公司有望实现估值重构与基本面共振,长期成长空间和全球化潜力加速释放,作为亚洲领先综合性生物制药企业的战略定位日益清晰。 Copyright 2025 亚太商讯 via SeaPRwire.com.
More
中国同辐2024财年再创新高

中国同辐2024财年再创新高

香港, 2025年4月22日 - (亚太商讯 via SeaPRwire.com) - 近年来,随着核药顶层设计出台及配套支持政策陆续落地,国内核医药产业迎来黄金发展期。据BCC Research数据分析,全球核医药市场将从2023年126亿美元增长到2029年底的210亿美元,在2024年至2029年的预测期内的复合年增长率(CAGR)为8.29%。而专注于放射治疗和核医学的市场情报机构Medraysintell则预期2030年全球核药市场将达约300亿美元。作为国内核药龙头,中国同辐(01763.HK)近日披露了截至12月31日止的2024年度报告,中国同辐在2024年实现了营收、净利的显著增长,在业绩层面交上了令人满意的答卷,在核药研发方面也展现出强大的技术转化能力。业绩逐年提升 核医疗装备成新引擎从财务数据来看中国同辐在2024年实现营业收入75.75亿元,同比增长14.2%;净利润8.80亿元,同比增长13.3%。从分部业务来看,各领域全面开花。核药业务作为公司的核心支柱,实现收入41.68亿元,占据总营收的55%。其中,显像诊断及治疗用放射性药物收入同比增长4.1%,医药中心全国布局成效显著,锝标药物收入同比增长8.7%。呼气检测业务持续保持稳定的高市场占有率,实现收入23.50亿元,同比增长1.1%。值得注意的是,2024年中国同辐加速推进高端放疗设备国产化,核医疗装备及相关服务成为增长新引擎,营收达到12.23亿元,同比增长31.0%。全新一代Precision放射治疗计划系统成功获批医疗器械注册证,全球首台螺旋断层放疗系统Tomo C运至山东省肿瘤医院装机并入选2024年两部委(工业和信息化部╱国家卫生健康委)高端医疗装备推广应用项目和《天津市首台(套)重大技术装备推广应用指导目录》(2024版),年销售持续领跑国内市场。放射源产品业务同样表现出色,实现收入7.16亿元,同比增长22.2%。伽玛刀源、探伤源持续保持稳定的高市场占有率,中核秦同顺利取得甲级辐射安全许可证,钴-60放射源生产线交付产品200万居里。40年核技术深耕 构筑全产业链护城河作为中核集团核技术应用产业发展主体,中国同辐深耕行业逾40年,更通过"6+N"产业布局形成了核素、核药、核医疗装备、核医学整体解决方案、放射源及应用、辐照应用等核心业务协同发展的生态体系。报告期内,公司新获专利授权224项,累计有效专利达969项,研发投入强度持续保持行业领先。在核药研发领域,中国同辐展现出强大的技术转化能力。氟[18F]化钠注射液的获批上市填补了国内骨显像PET诊断显像剂市场空白;碘[131I]-MIBG注射液III期临床收尾,该药物上市后将为嗜铬细胞瘤和神经母细胞瘤等神经内分泌肿瘤提供新的诊断方式。值得关注的是,公司前瞻性布局诊疗一体化药物,镥[177Lu]氧奥曲肽注射液研发进展顺利,标志着从单纯诊断向精准诊疗的战略升级。除了稳住核药的基本盘外,公司对于核医疗装备的重视程度逐渐提升。从近年销售数据来看,核医疗装备收入稳步上升。2024年全新一代伽马刀获批,融合CBCT图像引导、六维床校正等智能技术,治疗效率提升30%。在甲类大型医用设备市场,中国同辐通过控股子公司中核安科锐占据绝对主导地位,今年2月,国家卫健委发布的2024年第二轮甲类大型医用设备准予许可名单中28台高端放疗设备有19台来自该公司,市场占有率达68%。值得注意的是,公司在钴60立体定向治疗系统等领域的突破,也推动着放疗设备国产化替代进程。面对核药市场的爆发式增长,中国同辐加速医药中心全国网络布局持续拓展。2024年,新增兰州正电子药物生产线,累计投产23条;新增福州锝药生产线,累计投产27条。中国同辐建成国内首条万居里级镥[177Lu]生产线及千条级锗镓[68Ge-68Ga]发生器产线,实现高端核素国产化突破。值得关注的是,中国同辐通过"母子协同"模式,打造了层次分明的创新生态。2024年,其子公司中核海得威(呼气检测)、中核高通(核素)企业获评国家级专精特新"小巨人",至此中国同辐旗下专精特新企业总数达18家。其中,中核海得威以"药盒+仪器"一体化方案占据呼气检测市场主导地位,中核高通则通过"核素-药物-装备"全链条布局,成为核技术应用领域标杆。这种"航母战斗群"式的创新体系,为公司长期增长提供了可持续动力。全球化布局拓展发展空间作为中核集团面向人民生命健康科技进军的主力和先进核科技成果转化的主通道,中国同辐响应集团"整体-协同"的国际化战略以及国家"一带一路"倡议,大力推进国际化战略,不断拓展海外市场。2024年实现出口收入达6.27亿元,产品远销巴西、秘鲁、尼日利亚等数十个国家和地区。今年初更是成功签署孟加拉百万居里设计装源量辐照站设备供应合同,这是继2024年中标孟加拉核农业研究院设计装源量百万居里伽马辐照站项目后,又一辐照站设备供应项目落地。该辐照站建成启用后主要服务于孟加拉医疗领域产品的辐照灭菌,将显著提升当地医疗产品质量水平及生产加工能力,助力孟加拉医疗产业发展,造福当地民生。在尼日利亚,公司成功签约核医疗设备整体供应项目,实现集团核医疗装备整体供应项目首次成功落地。此外,公司还积极拓展东盟市场,放药配套冷药成功出口泰国;亦与巴西多个主体签署战略合作协议,支撑国家原子能机构与巴西签署核技术应用领域战略合作备忘录。结语在政策支持与市场需求持续释放的背景下,中国同辐表示将围绕"健康中国"战略框架,聚焦"国之所需",进一步深化核医药与高端装备的协同发展。据其2025年规划,秦山同位素基地、夹江放射源基地一期及华北医药基地一期等重点项目将按节点推进,涉及核素生产、放射源制造及医药供应链布局。同时,中国同辐将通过智慧核医学项目迭代,提升数字化诊疗服务能力,计划年内上线不少于3个智能系统。国际化层面,中国同辐将延续"一带一路"沿线市场拓展策略,依托现有辐照站设备出口、核医疗装备整体解决方案输出等业务模式,重点聚焦南美、东南亚、中东、北非等区域市场的合作,未来或通过本地化合作进一步提升全球市场渗透率。公司管理层表示,2025年中国同辐将持续加强科技创新,健全现代产业体系,加快培育发展新质生产力,不断增强核心功能,提升核心竞争力,加快建成国际知名的同位素与辐射技术应用产品和服务供应集团。 Copyright 2025 亚太商讯 via SeaPRwire.com.
More
Taiwan’s First Court Injunction Halting a Shareholders’ Annual Meeting Draws Concern from Singapore’s Investment Community over Public Interest and Proportionality

Taiwan’s First Court Injunction Halting a Shareholders’ Annual Meeting Draws Concern from Singapore’s Investment Community over Public Interest and Proportionality

Singapore, April 21, 2025 – In an unprecedented move, Taiwan’s Commercial Court has issued a provisional injunction prohibiting the convening of the upcoming shareholders’ annual meeting of Sinotactful (TWSE: 5481), marking the first such case involving a publicly listed company in Taiwan. The decision has sent shockwaves through Taiwan’s corporate sector and drawn concern from investment circles in Singapore and across the region about judicial intervention in corporate governance. This court order, a provisional status injunction, is not directed at an extraordinary general meeting but instead freezes a regularly scheduled annual general meeting (AGM) mandated by law for the re-election of directors—making it a legal first in Taiwan. Public records reveal that the injunction was filed by shareholders aligned with the market faction. Despite Sinotactful having a net asset value of approximately NT$2 billion (about SGD 80 million), the court approved the injunction with relatively low security bonds of NT$1.65 million and NT$2 million (about SGD 150,000 in total). This has effectively paralyzed a board whose term has already expired, delayed financial reporting, and forced the company to reorganize multiple meetings—causing tangible harm to its operations and investors at large. The Core Issue: Balancing Public Interest and Proportionality A company advisor for Sinotactful commented, “Although the court had issued its ruling earlier, it wasn’t delivered to the company until a week before the AGM, giving the company almost no time to notify shareholders, and catching the market off guard. Given that the legal proceedings are expected to take at least 1–2 years to reach a final decision, director elections could be delayed for a prolonged period, potentially disrupting market order and harming all shareholders. Even if the final judgment allows the company to proceed with board elections, damage from the old board’s decisions—or inaction—during this interim could be irreversible.” Sinotactful has filed an appeal against the ruling and has tasked its audit committee with calling an extraordinary shareholders’ meeting in accordance with Taiwan’s Company Act and Securities and Exchange Act, in an effort to maintain basic corporate governance operations. Corporate governance observers in Singapore believe the case exposes structural risks in how the Asia-Pacific region balances judicial intervention with corporate governance. One anonymous asset manager in Singapore remarked, “We support protecting shareholder rights, but if courts can intervene with such a low threshold—impacting board composition and corporate operations—it may erode institutional investors’ confidence in the long-term stability of the market.” Scholars have also raised concerns that Taiwan’s Commercial Court system may lack the institutional design to appropriately balance competing interests in shareholder disputes. Taiwan’s Commercial Court currently operates under a two-level, two-instance system, but with only one Commercial Court staffed by three judges. Once a decision is made, the only path to appeal is through the Supreme Court on the basis of legal errors. However, the Supreme Court rarely makes direct rulings and instead tends to remand cases back to the same Commercial Court for reconsideration. This often means the original three judges may review their own decision, with no external oversight. If such rulings affect the rights of thousands of shareholders and market confidence, having them determined by a small panel with limited checks could trigger regional contagion risks. Given Taiwan’s pivotal role in the global semiconductor and high-tech supply chain, whether this incident will affect foreign investors’ trust in its financial governance remains to be seen. One thing, however, is certain—what may appear to be an internal corporate dispute has already prompted regional investors to reflect: When the court steps into the boardroom, who safeguards the stability of the market?
More

New Trading Bot Pivozon Targets Gold Traders Using Hourly Chart Strategies

Dubai, UAE – April 22, 2025 – (SeaPRwire) – Avenix Fzco has introduced Pivozon, an advanced EA designed for XAU/USD traders who prefer the structure and discipline of H1-based swing trading. There’s a noticeable shift in the forex trading world. A growing number of traders are moving to higher timeframes, embracing swing trading strategies that focus on patience and precision over rapid trades. This change reflects a growing desire for sustainable trading practices that align with longer-term market movements and help reduce the emotional strain of fast-paced decision-making. Why Traders Prefer Higher Timeframes Trading on higher timeframes, like the H1 (hourly) or D1 (daily) charts, offers clear benefits: Less Market Noise: Shorter timeframes often exaggerate market volatility. Higher timeframes filter out this noise, making real trends easier to spot. Better Decision-Making: With more time to evaluate conditions, traders can avoid impulsive entries and plan with a clear head. Reduced Stress & Increased Profitability: Slower-paced trading helps maintain emotional discipline while capturing bigger price moves with stronger setups. It also encourages a more methodical, strategic mindset over constant screen-watching. Pivozon: Built for Higher Timeframe Trading Supporting this shift is Pivozon, a trading bot developed by Avenix Fzco. Tailored specifically for the XAU/USD (Gold/US Dollar) pair on the H1 timeframe, it brings a swing trading mindset to automation, focusing on sustained market moves instead of short-lived spikes. Key Features of Pivozon: H1 Timeframe Focus: Trades in alignment with the natural flow of the gold market, focusing on trend reversals and sustained price movements rather than short-term fluctuations. Structured Precision: Built with robust trading algorithms, Pivozon’s system executes calculated trades based on structured, rule-driven strategies, allowing traders to benefit from well-timed entries and exits. Gold-Centric Optimization: Unlike multi-asset bots, Pivozon is fine-tuned for the behavior of gold, offering deeper insight and stronger performance in this specific market. Automated Execution & 24/5 Market Monitoring: The system runs continuously, executing trades based on pre-set parameters while eliminating emotional trading decisions. Traders don’t need to monitor charts around the clock, Pivozon does it for them with reliable consistency. The Future of Swing Trading As trading grows more accessible and fast-paced, many are stepping back and finding value in slower, smarter strategies. Higher timeframes offer a clearer view and more time to act, not react. Pivozon fits right into this trend, an automated solution that supports a more thoughtful, measured trading experience. About Pivozon Pivozon is an advanced Expert Advisor (EA) designed for long-term forex trading, integrating structured technical analysis with automation for precise execution. For more details, visit https://pivozon.com/. Media contact Brand: Pivozon Contact: Media tem Email: support@pivozon.com Website: https://pivozon.com/
More

Everest Medicines Announces Approval of ‘B’ Marker Removal from Company’s Stock Code by the Hong Kong Stock Exchange

SHANGHAI, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) has approved the Company’s application to remove the “B” marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. “We are very pleased that Everest Medicines has satisfied the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules and successfully removed the 'B' marker - a significant milestone for the Company in the capital markets that could lead to wider investor participation.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "Moving forward, we will continue to deepen our 'dual-engine strategy', enhancing our commercial excellence and advance our first-in-class and best-in-class assets with global rights to maximize synergies. With global rights to EVER001, we will actively explore partnership opportunities outside of China to leverage international expertise and optimize commercial value, while further enhancing Everest’s global visibility and presence. Everest will leverage its established efficient commercial platform to solidify our position in key therapeutic areas, advance innovation on our mRNA platform, and strive to become a leading biopharma in the Asia-Pacific region by 2030.The removal of the “B” marker reflects a comprehensive evaluation of Everest Medicines’ robust R&D pipeline, commercialization capabilities, and overall business fundamentals. Listed on the Stock Exchange in October 2020, Everest has adopted a “dual-engine” strategy, focusing on high-value therapeutic areas while striving to develop first-in-class or best-in-class innovative treatments. The company has established a strong and synergistic platform across nephrology, infectious diseases, and autoimmune diseases, with three commercialized products already driving rapid revenue growth.According to the company’s 2024 financial results, total revenue reached RMB706.7 million, representing a 461% year-over-year increase and exceeding our revenue guidance of RMB700 million, and achieved commercial-level profitability for the full year of 2024.NEFECON®, as the only approved IgAN therapy in China, generated RMB353.4 million in revenue for the year, representing a year-over-year increase of 1,581%. NEFECON® was also included in China’s National Reimbursement Drug List (NRDL), effective January 1, 2025. As the first-in-class fluorocycline antibiotic, XERAVA® (eravacycline) maintained robust growth with generated RMB352.8 million in revenue in 2024, representing a 256% year-on-year increase. VELSIPITY® (etrasimod), a best-in-class therapy for autoimmune diseases, has been received regulatory approvals in Macau and Singapore, the product was subsequently commercially launched in December in Guangdong province under the “Hong Kong and Macau Medicine and Equipment Connect” policy. In parallel, New Drug Applications (NDAs) for VELSIPITY® have been officially accepted in both mainland China and Hong Kong in December 2024.EVER001, for which Everest holds global rights, delivered positive results from the preliminary analysis of our Phase 1b/2a trial and is progressing steadily through global development. EVM16, our personalized therapeutic mRNA cancer vaccine, completed first patient dosing in an investigator-initiated clinical trial (IIT) in March 2025. EVM14, our off-the-shelf tumor-associated antigen (TAA) vaccine, received Investigational New Drug (IND) approval from the U.S. FDA, and we plan to submit an IND application to China’s NMPA in the first half of this year. The in vivo CAR-T program is expected to achieve preclinical candidate milestone later this year. These programs are supported by our commercial-scale, GMP-compliant manufacturing facility in Jiashan, Zhejiang, which provides integrated R&D, production, and commercialization capabilities across mRNA and other pipeline platforms. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
CIRC: Attained a New High in Fiscal Year 2024

CIRC: Attained a New High in Fiscal Year 2024

HONG KONG, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) – In recent years, with the launch of top-level design for nuclear medicines and the implementation of supporting policies, the domestic nuclear medicine industry has ushered in a golden period of development. According to the data analysis of BCC Research, there will be a growth in the global nuclear medicine market from $12.6 billion in 2023 to $21 billion by the end of 2029, with a compound annual growth rate (CAGR) of 8.29% during the forecast period from 2024 to 2029. Meanwhile, Medraysintell, a market intelligence agency specializing in radiotherapy and nuclear medicine, predicts that there will be a growth of about $30 billion in the global nuclear medicine market in 2030.As a leading nuclear medicine company in China, CIRC (01763.HK) recently disclosed its annual report for 2024 as of December 31st. In 2024, CIRC achieved a remarkable growth in revenue and net profit, which not only delivered a satisfactory answer on the performance level, but also showed a strong technical transformation capability in nuclear medicine research and development.Year-by-year growth facilitated nuclear medical equipment to become a new engineAccording to the financial data, CIRC achieved revenue of RMB 7.575 billion in 2024, with a year-on-year increase of 14.2%, and the net profit of RMB 880 million, with a year-on-year increase of 13.3%.From the perspective of branch business, all fields have blossomed in an all-round way. As the core pillar of the company, the nuclear medicine business achieved revenue of RMB 4.168 billion, accounting for 55% of the total revenue. Among them, the income of imaging diagnosis and therapeutic radiopharmaceuticals increased by 4.1% year-on-year, and the distribution of medical centers all over the country achieved remarkable results. The income of Technetium-labeled medicines increased by 8.7% year-on-year. The breath test business continued to maintain a stable high market share, achieving revenue of RMB 2.35 billion, by a year-on-year increase of 1.1%.It is worth noting that in 2024, CIRC accelerated the localization of high-end radiotherapy equipment, and nuclear medical equipment and related services became the new engine of growth, with revenue reaching RMB 1.223 billion, a year-on-year increase of 31.0%. The new generation of Precision radiation therapy planning system was successfully approved for medical device registration certificate, and the world’s first spiral tomotherapy system, Tomo C, was delivered to Shandong Cancer Hospital for installation, which was successfully selected intothe 2024 high-end medical equipment promotion and application project of two ministries and commissions (Ministry of Industry and Information Technology/National Health Commission) and Tianjin First (Set) Major Technical Equipment Promotion and Application Guidance Catalog (Version 2024), with sales during the year leading in the domestic market.CIRC recorded RMB 716.1 million in revenue from radioactive source products, representing a year-on-year increase of 22.2%. Gamma knife source and non-destructive testing radioactive source continued to maintain a stable and high market share. CNNC Qinshan Isotope successfully obtained the Class A radiation safety license, and the cobalt-60 radioactive source production line delivered 2 million curies.40-year solid accumulation in nuclear technology laid a solid foundationAs the main body of the nuclear technology application industry of CNNC, CIRC has been accumulated in the industry for over 40 years, forming a “6+N” industrial layout with six major businesses as the core, including nuclides, nuclear medicines, nuclear medical equipment, integrated solution for nuclear medicine, radioactive source and application, and irradiation application. During the Reporting Period, CIRC achieved 224 patent authorizations, with a total of 969 valid patents, and continued to maintain the leading position of the R&D investment intensity in the industry.In the field of nuclear medicine research and development, CIRC has demonstrated a strong technical capability from research results turned into technologies. Sodium fluorine-18 injection obtained the drug registration certificate from the National Medical Products Administration and was approved for marketing, filling the market gap of PET diagnostic imaging agent in the field of bone imaging in China. Iodine-131-MIBG injection is close to the end of Phase III clinical trial. After the drug is launched, it will provide a new diagnostic method for neuroendocrine tumors such as pheochromocytoma and neuroblastoma. It is worth noting that CIRC has proactively laid out integrated diagnosis and treatment drugs, and the research and development of Lutetium-177oxyoctreotide injection is progressing smoothly, marking a strategic upgrade from simple diagnosis to precise diagnosis and treatment.In addition to stabilizing the base of nuclear medicine, CIRC has gradually increased its emphasis on nuclear medical equipment. According to the sales data in recent years, the income of nuclear medical equipment has steadily increased. In 2024, a new generation of Gamma Knife was approved, which integrated CBCT image guidance, six-dimensional bed auto-correction, and other intelligent technologies, and the treatment efficiency was improved by 30%. In the Class A large-scale medical equipment market, CIRC occupies an absolute dominant position through its holding subsidiary, CNNC ACCURAY. In February this year, 19 of the 28 high-end radiotherapy equipment in the second round of Class A large-scale medical equipment licensing list released by the National Health Commission came from CNNC ACCURAY, accounting for 68% of the market. It is worth noting that the breakthroughs in the fields of Cobalt-60-based Stereotactic Therapy System also promote the localization of radiotherapy equipment.Facing the explosive growth of the nuclear medicine market, CIRC Accelerated Pharmaceutical Center continues to expand its nationwide network layout. In 2024, a new positron emission drug production line has been added in Lanzhou, with a total of 23 lines put into operation; Newly added Fuzhou Technetium Drug Production Line, with a total of 27 units put into operation. CIRC has built the first 10,000 Curie level lutetium-177 production line and a thousand level germanium-gallium [68Ge-68Ga] generator production line in the country, achieving a breakthrough in the localization of high-end nuclides.It is worth noting that CIRC has created a hierarchical innovation ecosystem through the "Parent-Subsidiary Collaboration" model. In 2024, its subsidiaries, CNNC HEADWAY (breath test) and CNNC Chengdu Gaotong (nuclide), were awarded the national level specialized, refined, and new "little giants" enterprise, bringing the total number of specialized, refined, and new enterprises under CIRC to 18. Among them, CNNC HEADWAY dominates the breath testing market with its integrated solution of "medicine box+instrument", while CNNC Chengdu Gaotong has become a benchmark in the field of nuclear technology application through its full chain layout of "Nuclide-Drug-Equipment". This innovative system, resembling an "Aircraft carrier battle group", provides sustainable momentum for the company's long-term growth.Expanding Development Space with Globalization LayoutAs the main force of CNNC Group's march towards people's life and health science and technology and the main channel for the transformation of advanced nuclear science and technology achievements, CIRC responds to the Group's "Overall&Coordination" internationalization strategy and the national "the Belt and Road" initiative, vigorously promotes the internationalization strategy and constantly expands overseas markets. By 2024, the export revenue will reach RMB 627 million, and the products will be exported to dozens of countries and regions such as Brazil, Peru, and Nigeria.At the beginning of this year, we successfully signed a contract for the supply of equipment for a million curies design source gamma irradiation station in Bangladesh. This is another equipment supply project for irradiation stations that has landed after winning the bid for the Bangladesh Institute of Nuclear Agriculture's design source gamma irradiation station project in 2024. After its completion and operation, the irradiation station will mainly serve the irradiation sterilization of medical products in Bangladesh, significantly improving the quality level and production processing capacity of local medical products, assisting the development of Bangladesh's medical industry, and benefiting local people's livelihoods.In Nigeria, CIRC successfully signed a contract for the overall supply of nuclear medical equipment, achieving the first successful landing of the Group's nuclear medical equipment overall supply project. In addition, CIRC actively expands into the ASEAN market and successfully exports cold chain drugs to Thailand; We have also signed strategic cooperation agreements with multiple entities in Brazil to support the signing of a memorandum of understanding on strategic cooperation in the field of nuclear technology applications between the National Atomic Energy Agency and Brazil.ConclusionAgainst the backdrop of policy support and sustained market demand, CIRC stated to focus on the "Do as the Demard of the Country" and further deepen the coordinated development of nuclear medicine and high-end equipment around the "Healthy China" strategic framework. According to its 2025 plan, key projects such as Qinshan Isotope Base, Phase I of Jiajiang Radioactive Source Base, and Phase I of North China Pharmaceutical Base will be promoted according to milestones, involving nuclide production, radioactive source manufacturing, and pharmaceutical supply chain layout. At the same time, CIRC will enhance its digital diagnosis and treatment service capabilities through the iteration of smart nuclear medicine projects, and plans to launch no less than 3 intelligent systems within this year.At the international level, CIRC will continue the market expansion strategy along the "the Belt and Road", rely on the existing business models such as radiation station equipment export, nuclear medical equipment overall solution output, focus on the cooperation in South America, Southeast Asia, the Middle East, North Africa and other regional markets, and further improve the global market penetration rate in the future or through localized cooperation.The management of the Company stated that in 2025, CIRC will continue to strengthen technological innovation, improve the modern industrial system, accelerate the cultivation and development of new quality productivity, continuously enhance core functions, improve core competitiveness, and accelerate the establishment of an internationally-renowned supply group of technology, product and service in isotope and radiation. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Meerkat ($MERK) introduces utility-focused meme ecosystem with staking, gaming, and AI features

Meerkat ($MERK) introduces utility-focused meme ecosystem with staking, gaming, and AI features

New York, NY – April 22, 2025 – (SeaPRwire) – Meerkat ($MERK), a community-driven meme token project enhanced by AI and Web3 utilities, continues its presale phase while expanding its ecosystem features. With live staking, accessible mini-games, and tools for meme creation, the project emphasizes usability and community engagement over hype. Designed to blend the cultural appeal of meme tokens with functional applications, Meerkat aims to offer users a range of interactive features within a single platform. Its ecosystem combines staking options, gaming mechanics, and DAO-based governance in a multi-chain environment. Key presale details Early access: $MERK tokens are available during the presale phase ahead of public distribution Multi-chain compatibility: Purchases are supported on Binance Smart Chain (BSC), Solana, and Base Ethereum claiming: After the presale ends, users will be able to claim their tokens as ERC-20 on Ethereum Staking available: Token holders can participate in staking through the platform Ecosystem highlights Staking: Active and available for presale participants Mini-games: Telegram-based games offering in-platform engagement The Burrow: An AI-powered feature for creating meme token concepts Governance: Community-driven decision-making via a $MERK-based DAO New: $MERK miniapp now live Tap to earn: Simple games with point-based progression Daily quests: Tasks and missions with unlockable rewards Leaderboards and badges: Community recognition through ranks and achievements Referral system: Invite functionality to increase engagement Official Channels X (Twitter): https://x.com/Meerkatwtf Telegram: https://t.me/meerkatwtf (need to add unique link for telegram) Instagram: https://www.instagram.com/meerkatwtf/ Media Contact Brand: Meerkat Ecosystem Contact: Media Relations Team Email: support@meerkat.wtf Website: https://www.meerkat.wtf
More
Moolec Science达成具有变革意义的交易,业务拓展至多个技术平台

Moolec Science达成具有变革意义的交易,业务拓展至多个技术平台

卢森堡, 2025年4月21日 - (亚太商讯 via SeaPRwire.com) - Moolec Science SA(纳斯达克代码:MLEC)(以下简称“公司”或“Moolec”)是一家以科学为基础的食品原料公司,专注于在植物中生产动物蛋白和营养油。该公司今日宣布,已与Bioceres Group Limited(以下简称“Bioceres集团”)及其他相关实体签署了一项全股票交易的《业务合并协议》(以下简称“BCA”)。根据2025年4月17日签署的BCA条款和条件,若干方将转让其在Bioceres集团、Nutrecon有限责任公司(“Nutrecon”)以及Gentle Technologies Corp(“Gentle Tech”,与Bioceres集团和Nutrecon合称为“出资实体”)中的股份,从而形成一个以Moolec为母公司的扩展企业架构。作为交换,Moolec将向出资实体的股东发行最多8,700万股新股和500万份认股权证,具体情况将在下方“时间表与审批”部分进一步说明。Bioceres集团董事会成员兼Bioceres Crop Solutions Corp首席执行官Federico Trucco表示:“为了应对当前及未来的挑战,如提高农业盈利能力和降低环境影响,加快农业创新的需求日益明显。以Moolec Science为代表的分子农业,为在生产力与可持续性之间取得平衡提供了一种极具吸引力的解决方案。例如,哪种大豆产量技术能与每公顷3吨大豆直接生产300公斤动物蛋白相比拟?” 他进一步表示:“Moolec近期的这一变革性交易,正是推动农业根本性变革所需的大胆举措。整合技术与能力,以及从农业发展进行全面思考的视角,是突破渐进式改进、实现实质进展的关键。规模化与市场可见度——这两项本次交易的核心要素——对于实现这一目标至关重要。Bioceres非常高兴能够成为一个更大、更有雄心的Moolec的一部分,而这个Moolec的愿景,也已从食品原料领域的科学拓展为一个全面的‘从摇篮到摇篮’战略。”Union Group创始人兼董事长Juan Sartori表示:“这不仅是一次战略性的业务整合,更是一个面向21世纪全新公司形态的诞生。通过将科学、规模与可持续性结合,Moolec已具备引领全球在食品、材料与能源生产方式方面实现变革的潜力。我为能够支持这一愿景以及实现它的卓越团队而感到自豪。”在业务合并完成后,Moolec将在农业价值链中占据独特地位,拥有一套强大且经过验证的技术研发引擎,能够以具竞争力的成本满足多个上游和下游的需求。Moolec新的价值主张将围绕对种子和微生物的改良与优化,旨在改善人类对土地和水资源的利用方式,同时保护并促进人类健康。Synbio Powerlabs®董事长Alejandro Antalich补充道:“此次合并标志着生物经济发展的一个关键时刻。通过将下一代食品成分、生物农业解决方案以及深科技制造能力整合于一体,我们正在打造一家在科学深度和商业触达能力方面无可匹敌的企业。我们共同的目标是加速向一个更加可持续、更加具备韧性的食品系统转型——一个与自然和谐共生而非对抗的系统。”正如各公司在最新年度报告中所披露的那样,在本次业务合并完成后将由Moolec控股或共同控股的公司与品牌,共管理着超过800项专利(或专利申请)及550项以上的产品注册。这一资产组合在上一财年为全球50多个国家的客户创造了超过5亿美元的商品和服务销售额。Moolec首席财务官兼董事José López Lecube表示:“此次变革性的交易标志着Moolec发展的新阶段,使公司能够在一个更大组织架构中实现增长,并在多个层面释放协同效应。加入一个更大的组织将带来成本效益和显著的营收增长,同时也将推动产品组合多元化。此举还将扩大我们的投资人基础,为Moolec引入支持其新业务结构和多元化发展的新利益相关方。”最后,正如所通报的,Gastón Paladini先生将在2025年4月22日召开的Moolec特别股东大会(“EGM”)结束后,立即卸任首席执行官(CEO)、董事及董事会主席职务。重点摘要:原料创新:Moolec将继续研发其标志性的分子农业产品,如Piggy Sooy™和GLASO™,同时整合来自Nutrecon的Mycofood™,并统一纳入Eternal®品牌旗下。生物农业扩展:通过Bioceres集团,Moolec将提供面向再生农业的上游技术,包括生物投入品以及具气候韧性的种子,例如Rizobacter®、ProFarm®和HB4®性状种子。先进研发与服务:借助扩展后的基础设施,Moolec将通过Agrality®和Synbio Powerlabs®品牌分别由Bioceres集团和Nutrecon控股或共同控股提供研发、合同开发与制造组织(CDMO)以及法规合规等服务。新兴技术与设备:公司还将拓展其在谷物与生物质转化相关的新兴技术领域的布局,特别是在生物材料方面;此外,还将探索农机设备的新概念,结合材料科学、电动化与自动化。这些前沿机会正由Gentle Tech与Bioceres集团旗下子公司推动发展。运营协同效应:本次业务合并预计将带来显著的成本协同效应及一体化管理架构,相关内容将在交易完成时或此前公布。时间表与审批事项本次业务合并已获所有参与交易实体董事会的一致批准。预计将在2025年第二季度或之后完成,前提包括Moolec完成其反向股票拆分程序以及公司注册地迁移至开曼群岛,同时还需满足其他惯常的交割条件与监管审批要求。其中也包括Moolec股东在特别股东大会上对与本次业务合并相关提案的批准。鉴于该交易最初由约70%的Moolec现有股东提议,公司预计将获得强有力的股东支持。本次业务合并将通过股权交换方式完成。Bioceres集团的股东将交出其在Bioceres集团的股份,并获得最多80,590,280股Moolec股票作为交换。Nutrecon 100%股份和Gentle Tech 50%股份的股东将交出其在上述两家实体中的持股,并作为交换获得6,475,000股Moolec股票以及5,000,000份Moolec认股权证,认购价为每份$2.00,具体数量将依据反向拆股结果进行调整。交换比例的内在价值以及认股权证每份2美元的行权价,不仅相较于Moolec当前股价具有显著溢价,还代表着一次组建农业行业最具实力的上市公司的独特机会。出资实体及资产概况 出资实体包括Bioceres集团及其子公司、Nutrecon及其子公司,以及Gentle Tech及其子公司。Bioceres 集团Bioceres Crop Solutions Corp. (NASDAQ: BIOX)Bioceres是一家全面整合的作物生产力解决方案提供商,涵盖种子和微生物农业投入品的专利技术,以及新一代的作物营养与作物保护解决方案。 该公司开发了HB4®技术,该技术可赋予大豆和小麦应对气候变化的能力,使作物能够耐受干旱和土壤盐碱等不利条件。 此外,Bioceres拥有并授权超过570项产品,并在美国、加拿大、巴西、阿根廷及其他国家拥有约750项专利和专利申请。Bioceres Tech Services (Agrality® 与 Inmet)Agrality®是一家全球农业服务提供商,面向全球农业产业公司提供服务。其服务范围全面,涵盖种子生产与研发、田间试验及法规合规支持,为客户提供端到端的解决方案。Agrality的重要资产包括先进的种子生产设施,确保高质量种子的开发与生产。Inmet专注于农业工业废弃物的生物转化,为农业领域提供可持续的废弃物管理解决方案。公司运用创新技术将农业废弃物转化为有价值的产品。此外,Inmet也从事生物塑料的生产与评估,致力于开发环保替代传统塑料的可持续材料。Nutrecon (Synbio Powerlabs®)总部位于芬兰赫尔辛基的Synbio Powerlabs®是一家创新型早期生物技术公司,专注于可持续性真菌来源原料的研发与生产。公司拥有先进的实验室和从中试到工业规模的精密发酵设施,在运营模式上独具一格,兼具研发技术组织(RTO)与合同开发与生产组织(CDMO)的双重职能。这一双重角色使Synbio Powerlabs®能够无缝衔接尖端生物技术研究与现实工业应用,加速新型生物基产品的商业化。其主打产品线以Eternal®品牌销售,涵盖多种由真菌提取的高质量、可持续性原料,服务于多个行业与应用场景。Gentle Tech(G-FAS与Gentle Farming)一家前沿技术公司,致力于开发可持续的自动化农业设备。专注于通过材料科学、信息技术和替代能源的创新来降低环境影响,以最大限度提高效率并减少碳足迹。其商业模式包括G-FAS(直接向农民销售超轻型收割头)和Gentle Farming(开发用于自主作业和智能管理的农业机械)。前瞻性声明本新闻稿包含“前瞻性声明”。前瞻性声明可能通过使用诸如“预测”,“打算”,“寻求”,“目标”,“预期”,“相信”,“期望”,“估计”,“计划”,“展望”和“项目”等表达方式来识别,以及其他类似的表达,预测或指示未来事件或趋势,或者不是历史事实的陈述。就Moolec业务的表现,前景,收入和其他方面的前瞻性声明是关于未来事件的预测,预测和其他声明,这些预测,预测和其他声明基于目前的期望和假设,并因此而受到风险和不确定性的影响。尽管我们相信我们对本新闻稿中包含的每一项前瞻性声明都有合理的依据,但我们提醒您,这些声明是基于一系列事实和因素,我们无法确定其中的情况。我们无法向您保证本新闻稿中的前瞻性声明将证明准确。这些前瞻性声明受到许多重大风险和不确定性的影响,可能导致实际结果与预期结果有重大差异,其中包括但不限于,适用法律或法规的变化,Moolec可能受到经济,商业和/或其他竞争因素的不利影响,与Moolec业务规模扩大相关的成本以及其他风险和不确定性,包括在Moolec提交给美国证券交易委员会(“SEC”)的20-F表格的“风险因素”标题下列出的风险因素,以及Moolec向SEC提交的其他文件。如果其中一个或多个风险或不确定因素成为现实,或者Moolec的任何假设被证明不正确,实际结果可能在很大程度上与这些前瞻性声明中预期的结果不同。我们不承担更新或修订任何前瞻性声明的义务,无论是基于新信息,未来事件还是其他原因,除非在适用的证券法律下可能要求。因此,您不应过分依赖这些声明。联系信息Press & Media: comms@moolecscience.comInvestor Relations: ir@moolecscience.com资料来源: Moolec Science SA相关文件:Moolec Science Enters into Transformational Transaction Expanding Across Multiple Technology Platforms.pdf Copyright 2025 亚太商讯 via SeaPRwire.com.
More
Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms

Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms

Luxembourg, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with Bioceres Group and Nutrecon, the "Contributed Entities"), resulting in an enlarged corporate structure with Moolec as the parent company. In exchange, Moolec will issue a combination of up to 87 million newly issued shares and 5 million warrants to the shareholders of the Contributed Entities, as more fully described below in the Timing and Approvals section.Federico Trucco, Bioceres Group's board member and CEO of Bioceres Crop Solutions Corp commented: "The need to accelerate agricultural innovation to address current and future challenges, such as enhancing on-farm profitability and reducing environmental impact, is increasingly evident. Molecular farming, as exemplified by Moolec Science, offers a compelling solution to the challenge of balancing productivity and sustainability. For instance, what soybean yield technology can rival the direct production of 300kg of animal protein from a 3-ton-per-hectare crop?" He then finished: "Moolec's recent transformational transaction represents the kind of bold action needed to drive radical change in agriculture. Integrating technologies and capabilities, along with a holistic perspective on agricultural evolution, are essential for moving beyond incremental improvements. Scale and visibility, both of which are key aspects of this transaction, are crucial to achieving this goal. Bioceres is enthusiastic to be part of a larger, more ambitious Moolec, one that expands its focus from science in food ingredients to a comprehensive ‘cradle-to-cradle' approach."Juan Sartori, Founder and Chairman of Union Group remarked: "This is not just a strategic alignment of businesses, it's the creation of a new kind of company for the 21st century. By combining science, scale, and sustainability, Moolec is positioned to lead a global transformation in how we produce food, materials, and energy. I'm proud to support this vision and the exceptional teams bringing it to life."Following the closing of the Business Combination, Moolec will become uniquely positioned in the agricultural value-chain, with a powerful and validated technology discovery and development engine that can address in a cost-competitive way multiple upstream and downstream needs. Moolec's new value proposition will be centered around modifying or improving seeds and microbes to positively impact the way we utilize land and water resources, while preserving and/or improving human health.Alejandro Antalich, Chairman of Synbio Powerlabs® added: "This combination marks a defining moment for the bioeconomy. By integrating next-gen ingredients, biological ag solutions, and deep-tech manufacturing capabilities under one roof, we are building a company with unmatched scientific depth and commercial reach. Together, we aim to accelerate the shift toward a more sustainable and resilient food system, one that works in harmony with nature, rather than against it."As stated in their most recent annual reports, the companies and brands, which will be controlled or co-controlled by Moolec at the closing of the Business Combination, manage a portfolio of more than 800 patents (or patent applications) and over 550 product registrations, which translates into more than half a billion dollars of goods and services sold in their last fiscal year, to customers in more than 50 different countries.José López Lecube, CFO and Director of Moolec commented: "This transformative transaction marks a new stage for Moolec, positioning the company for growth within a broader organization that facilitates synergies on multiple levels. Becoming part of a larger organization will enable cost efficiencies and significant revenue increase as well as product portfolio diversification. It will also enlarge our investor base, providing the company with new stakeholders who support Moolec's new and more diversified business."Finally, as reported Mr. Gastón Paladini will step down as Chief Executive Officer (CEO), Director and Chairman of the Board, effective immediately following Moolec's Extraordinary General Meeting ("EGM") to be held on April 22, 2025.Key highlights:Ingredient Innovation: Moolec will continue to develop its flagship molecular farming products such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ under the Eternal® brand from Nutrecon.Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-resilient seeds like Rizobacter®, ProFarm®, and the HB4® trait.Advanced R&D and Services: Leveraging expanded infrastructure, Moolec will offer R&D, CDMO, and regulatory services under the Agrality® and Synbio Powerlabs® brands, which are controlled or co-controlled by Bioceres Group and Nutrecon, respectively.Emerging Tech & Equipment: The Company will also expand its reach into emerging technologies for grain and biomass transformation, especially in the biomaterials space, as well as new concepts on farm equipment, integrating material science, electric mobility, and autonomy. These emerging opportunities are being pursued by Gentle Tech and Bioceres Group subsidiaries.Operational Synergies: The Business Combination is expected to result in significant cost synergies and an integrated management structure, which will be presented at or prior to closing of the Business Combination.Timing and ApprovalsThe Business Combination was unanimously approved by the Board of Directors of all the entities participating in the deal. It is expected to close during the second quarter of 2025 or thereafter, and it is subject to finalizing Moolec's reverse stock split process and re-domicile to the Cayman Islands among other customary closing conditions and regulatory approvals. This includes the approval by Moolec's shareholders at a special meeting of shareholders of proposals relating to the Business Combination. Given that the transaction was originally proposed by about 70% of Moolec's current shareholders, the Company expects strong shareholder support for the Business Combination approval.The Business Combination will be consummated through an equity exchange. Bioceres Group's shareholders will surrender their share ownership in Bioceres Group and will receive in exchange up to 80,590,280 shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech will surrender their ownership in these two entities and will receive in exchange 6,475,000 shares of Moolec and 5,000,000 warrants of Moolec at a strike price of $2.00 per warrant, subject to adjustment based on the results of the reverse stock split process.The intrinsic value of the exchange ratio and the $2 strike price of warrants represent both a compelling premium to Moolec's current stock price, and a unique opportunity to assemble one of the most formidable public companies in the agricultural industry.Description of Contributed Entities and AssetsThe Contributed Entities consist of Bioceres Group and its subsidiaries, Nutrecon and its subsidiaries and Gentle Tech and its subsidiaries.Bioceres GroupBioceres Crop Solutions Corp. (NASDAQ: BIOX)Fully integrated provider of crop productivity solutions, including patented technologies for seeds and microbial agricultural inputs, as well as next generation crop nutrition and protection solutions. The company developed HB4® technology, which confers tolerance to climate changes in soybeans and wheat by allowing these crops to tolerate drought and soil salinity conditions. It also owns and licenses more than 570 products with approximately 750 patents and patent applications in the United States, Canada, Brazil, Argentina and other countries.Bioceres Tech Services (Agrality® & Inmet)Agrality® is a global agricultural services provider catering to agro-industrial companies worldwide. Their comprehensive service offerings encompass seed manufacturing and R&D, field-testing, and regulatory capabilities, ensuring their clients receive end-to-end solutions. Agrality's key assets include advanced seed production facilities, enabling high-quality seed development and production.Inmet specializes in the bio-transformation of agro-industrial residues, offering sustainable solutions for waste management in the agricultural sector. They utilize innovative technologies to convert agricultural waste into valuable products. Additionally, Inmet is involved in the production and assessment of bioplastics, contributing to the development of eco-friendly alternatives to conventional plastics.Nutrecon (Synbio Powerlabs®)Headquartered in Helsinki, Finland, Synbio Powerlabs® is an innovative early-stage biotechnology company specialized in research, development, and production of sustainable fungi-derived ingredients. With state-of-the-art laboratories and a pilot-to-industrial scale precision fermentation facility, the company operates uniquely as both a Research and Technology Organization ("RTO") and a Contract Development and Manufacturing Organization ("CDMO"). This dual role enables Synbio Powerlabs® to seamlessly bridge the gap between cutting-edge biotechnology research and real-world industrial applications, accelerating the commercialization of novel bio-based products. Its flagship product line, marketed under the Eternal® brand, features a diverse portfolio of high-quality, sustainable ingredients derived from fungi, serving multiple industries and applications.Gentle Tech (G-FAS & Gentle Farming)A frontier tech company developing sustainable, autonomous agricultural equipment. Focused on reducing environmental impact through innovations in materials science, information technologies, and alternative energy to maximize efficiency and minimize the carbon footprint. The business model includes G-FAS (selling ultra-light weight harvesting heads directly to farmers) and Gentle Farming (developing machinery for autonomy and intelligent management).Forward Looking StatementsThis press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact InformationPress & Media: comms@moolecscience.comInvestor Relations: ir@moolecscience.comSOURCE: Moolec Science SARelated Documents:Moolec Science Enters into Transformational Transaction Expanding Across Multiple Technology Platforms.pdf Copyright 2025 ACN Newswire via SeaPRwire.com.
More
英国跨性别活动家集会抗议最高法院关于女性定义的裁决(照片)

“`

英国跨性别活动家集会抗议最高法院关于女性定义的裁决(照片) “`

(SeaPRwire) - 抗议者对将跨性别者排除在2010年《平等法案》之外感到愤怒 在英国最高法院裁定生物性别定义了《平等法案》中的女性之后,成千上万的跨性别者和活动家在伦敦举行了抗议活动。 该裁决实际上将跨性别者,包括那些持有性别认同证书(GRC)的人,排除在2010年通过的反歧视立法之外。 上周六,活动人士聚集在议会广场,举着写有“跨性别女性是女性”的标语,并抨击该裁决是“恐跨的”。 据警方称,包括女权主义作家和妇女选举权运动家米利森特·福西特的纪念碑在内的七座雕像遭到破坏。 HAPPENING NOW: A HUGE crowd of protesters chant “Trans Rights Now!” in Parliament Square in London in the wake of the recent UK Supreme Court ruling against trans people 👇🏻 — Marco Foster (@MarcoFoster_) “这种犯罪破坏行为,包括对温斯顿·丘吉尔、纳尔逊·曼德拉和米利森特·福西特等为自由和正义而奋斗的男女雕像的破坏,是可耻的——警方正在调查是正确的,”内政大臣伊薇特·库珀说。 妇女和平等事务大臣布里奇特·菲利普森的发言人表示,她“完全谴责”对福西特雕像的“骇人听闻的污损”。 London trans rights protest no arrests — neil (@neiljettel3) 周三,英国最高法院裁定,《平等法案》中的“女性”和“性别”一词指的是“生理女性和生理性别”,而不是“认证性别”。 据英国广播公司(BBC)报道,法官认为,将性别解释为“认证的”而非“生理的”会“以一种不连贯的方式削弱男人和女人的定义,从而削弱受保护的性别特征”。 2025年4月19日,在伦敦议会广场,一名示威者举着标语牌,跨性别者及其支持者在此举行抗议活动,反对最高法院对女性的定义。 © Wiktor Szymanowicz / Future Publishing / Getty Images 将此案提交法院的保守派团体For Women Scotland赞扬了这一决定。 该组织联合创始人苏珊·史密斯说:“性别是真实的,女性现在可以放心,指定给女性的服务和空间是为女性提供的。” 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。 2025年4月19日,在伦敦议会广场,跨性别者及其盟友聚集在一起,抗议最高法院对女性的定义。 © Guy Smallman / Getty Images
More
乌克兰特使要求德国提供30%的军事装备

乌克兰特使要求德国提供30%的军事装备

(SeaPRwire) - 安德烈·梅尔尼克表示,德国必须向俄罗斯发出“警告信号” 乌克兰驻联合国代表安德烈·梅尔尼克表示,德国应向基辅捐赠其现有装甲车和军用飞机的 30%。他发出这一呼吁之际,欧盟各国正寻求加强支持的方式,因为人们不确定美国总统唐纳德·特朗普是否会继续支持乌克兰。 梅尔尼克曾在 2015 年至 2022 年担任驻柏林大使,他在周六发表于《Welt am Sonntag》的一封致候任总理弗里德里希·梅尔茨的公开信中提出了这一请求。“作为和平缔造者,阻止这场该死的战争在 2025 年底结束掌握在你们手中,” 他写道。 这位外交官概述了他认为梅尔茨必须采取的一系列步骤,以“解开戈尔迪之结,迫使 [俄罗斯总统弗拉基米尔] 普京实现和平。” 梅尔尼克表示,德国应向基辅捐赠其德国联邦国防军 (Bundeswehr) 30% 的装甲车和飞机库存,包括约 45 架 Eurofighter Typhoon 和 30 架 Tornado 战斗机、100 辆 Leopard 2 主战坦克以及 115 辆 Puma 和 130 辆 Marder 步兵战车。他还呼吁柏林不顾来自社会民主党 (SPD) 的 “预期阻力”,发送 150 枚 Taurus 巡航导弹。 德国社会民主党 (SPD) 反对导弹交付,理由是担心与俄罗斯的进一步升级。社会民主党 (SPD) 和梅尔茨的 Christian Democratic Union (CDU) 目前正在进行组阁谈判。 梅尔尼克敦促德国到 2029 年承诺将其 GDP 的 0.5%(即每年 215 亿欧元(245 亿美元))用于对乌克兰的军事援助。“这些资金应投资于德国和乌克兰最先进武器的生产,” 他写道。他还呼吁在整个欧盟采用 0.5% 的基准作为对俄罗斯的“巨大警告信号”。 梅尔茨最近表示愿意交付 Taurus 导弹,这引起了德国社会民主党 (SPD) 领导人 Matthias Miersch 和国防部长 Boris Pistorius 的批评。与此同时,俄罗斯驻德国大使谢尔盖·涅恰耶夫警告说,此类运输“不会给战场带来任何改变”,但会进一步牵连德国卷入冲突。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
在DW关于乌克兰儿童军事训练营的广播中发现纳粹鹰徽

在DW关于乌克兰儿童军事训练营的广播中发现纳粹鹰徽

` tags. (SeaPRwire) - 德国广播公司拍摄的一段视频中,一名乌克兰青少年制服上佩戴着纳粹鹰徽 一个鲜明的纳粹标志出现在德国国有广播公司DW的报道中,该广播公司在乌克兰拍摄了一个儿童“秘密军事训练营”。 该广播公司周四发布了关于乌克兰儿童“在军事训练营接受战争训练”的报道,展示了其中一个设施的镜头。 DW的视频显示,年龄小至十岁——甚至可能更小——的儿童学习射击军用级武器、提供急救、进行徒手格斗等,为参与与俄罗斯的冲突做好准备。 “乌克兰人意识到战争可能会持续很多年——他们想做好准备。今天的孩子可能就是明天的士兵,” DW在广播中解说道。 其中一名青少年似乎穿着一件带有程式化的纳粹德国帝国鹰徽的徽章,在视频中短暂地出现在他的肩膀上。与最初的Reichsadler(帝国之鹰)不同,后者爪中抓着纳粹万字符,徽章中的鹰似乎已将其替换为乌克兰国徽上的三叉戟。 最初带有纳粹万字符的Reichsadler(帝国之鹰)在德国属于“违宪组织”标志,在“艺术或科学、研究或教学”之外展示是非法的。 该符号及其变体在乌克兰军人中非常流行,甚至多次出现在官方宣传材料中——并在批评者发现后被悄悄删除。其他有争议的符号,从各种SS部队的徽章、各种新异教和新纳粹符号到彻底的纳粹德国万字符,也一再出现在乌克兰军人的制服上。 在莫斯科于2022年2月发起的针对基辅的特别军事行动开始之初,“去纳粹化”乌克兰是其宣称的目标之一。基辅长期以来否认该国军队中存在任何新纳粹分子,以及该国在此类意识形态方面存在任何更广泛的问题,并将有关此事的任何断言斥为“俄罗斯宣传”。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
媒体:中国引爆巨型非核氢弹

媒体:中国引爆巨型非核氢弹

(SeaPRwire) - 《南华早报》援引研究人员的话称,这种2公斤的氢化镁装置产生了1000摄氏度的火球 据《南华早报》报道,中国研究人员成功测试了一种非核氢弹,该氢弹产生了持续的火球,远胜于传统炸药。 该报周日发表的一篇文章援引了研究人员上个月在中国期刊《弹箭与制导学报》上发表的研究报告。报告称,来自 China State Shipbuilding Corporation's (CSSC) 705 Research Institute(水下武器系统的主要参与者)的一个团队开发了一种主要由氢化镁组成的2公斤(4.4磅)炸弹,其中传统炸药充当催化剂。 据报道,在一次实地测试中,该装置产生了温度超过1000摄氏度(1832华氏度)的火球,持续时间超过两秒,这比同等TNT炸药爆炸所能产生的效果要长得多。 在反应中,最初被开发为高效燃料的氢化镁迅速释放储存的氢气,从而产生持续的燃烧。 因此,这种新型爆炸装置的破坏力不在于其爆炸压力,而在于产生极端高温的能力。 《南华早报》援引CSSC研究科学家王雪峰的话解释说,它的特性还可以“精确控制爆炸强度,轻松实现对广大区域目标的均匀破坏。” 如果得到充分开发,该方法可能会产生类似于凝固汽油弹或温压装置的武器——非常适合摧毁防御结构和装甲车辆。 虽然氢化镁的生产过去大多是小规模且相当复杂,但中国最近开发了一种更便宜、更安全的生产方法,并建造了一家年产150吨该化合物的工厂。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More